Affinity Asset Advisors’s Insmed INSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$78.5M Buy
480,000
+30,000
+7% +$4.61M 4.05% 5
2025
Q4
$78.3M Hold
450,000
4.46% 3
2025
Q3
$64.8M Sell
450,000
-25,000
-5% -$3.06M 5.65% 2
2025
Q2
$47.8M Buy
475,000
+335,000
+239% +$25.6M 6.53% 2
2025
Q1
$10.7M Buy
140,000
+90,000
+180% +$6.88M 1.02% 25
2024
Q4
$3.45M Hold
50,000
0.46% 45
2024
Q3
$3.65M Sell
50,000
-75,000
-60% -$5.53M 0.5% 50
2024
Q2
$8.38M Buy
+125,000
New +$4.85M 0.97% 32

Other funds holding INSM

Affinity Asset Advisors's INSM Position: Q1 2026 in Review

Affinity Asset Advisors increased its Insmed (INSM) stake by 6.7% in Q1 2026, buying an estimated $4.61M and bringing the position to 480,000 shares worth $78.5M. The position accounts for 4.05% of the portfolio, ranked #5.

Affinity Asset Advisors first reported a position in INSM in Q2 2024 and has held it in 8 quarters since. 669 funds tracked by Wall St. Rank hold INSM as of Q1 2026.

  • Affinity Asset Advisors held 480,000 shares of Insmed worth $78.5M as of Q1 2026.
  • Affinity Asset Advisors bought 30,000 Insmed shares in Q1 2026, an estimated $4.61M.
  • Insmed made up 4.05% of Affinity Asset Advisors's portfolio in Q1 2026, its #5 holding.
  • Affinity Asset Advisors first reported a position in Insmed in Q2 2024 and has held it in 8 quarters since.
  • 669 funds tracked by Wall St. Rank held Insmed as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.